No Data
No Data
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $131
UBS analyst Eliana Merle maintains $BioNTech(BNTX.US)$ with a hold rating, and adjusts the target price from $101 to $131.According to TipRanks data, the analyst has a success rate of 38.9% and a
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
Apple, Biontech, ResMed Among Morning Market Cap Stock Movers on Wednesday
UBS Maintains Neutral on BioNTech, Raises Price Target to $131
Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 3.75 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 17, $BioNTech(BNTX.US)$ 10% Stockholder ATHOS KG intends to sell 30,162 shares of its common stock on Sep 17, with a total market value of approximately $3.75 million.
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading